AVAN....---------->Great read from yahoo board.......
AVAN will take off: see my post #1037 on 12/20/99. The increase in share $ is for real and will continue for the following
reasons:
1) Generally, biotech is rebounding and a rising tide lift all boats, etc, etc.
2)Specifically, AVAN is still seriously undervalued at $200 mil market cap. AVAN has 10 therapeutics in clinical trials, and
some of these are potential blockbusters. If you look at a competitor like ALXN, which only has 5 candidates in the clinical
channel, and is valued at $500 mil, it is obvious that AVAN also should be valued at at least that cap, meaning that AVAN
should realistically be at about $8/sh. By the way, AVAN will probably get quicker approval for its complement inhibitor
than ALXN because it will apply for orphan drug status and then fast track it through the FDA. The results from the pediatric
surgery trials are very good, and going for this indication was a very shrewd business move on the part of AVAN
management.
3) The recent management hires have top reputations in the biotech/pharma industry: the fact that they joined AVAN shows
that they value the prospects of the company highly. As an investor, I have never gone wrong by following the moves of
those who have inside knowledge of the potential of a company.
4) I am a long term investor in the company, since its early days as TCell Sci, and as a biochemical researcher I have always
appreciated the quality of its science-the therapeutic products that have resulted from that research are about to confirm the
substantial potential of AVAN. |
